A Study of CTA30X Cell Injection in Patients With Relapsed or Refractory CD19-positive B-line Hematological Malignancies

CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma

NCT04649983 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

Clinical Study of CAR-iNKT Cells in the Treatment of Relapsed/Refractory/High-risk B-cell Tumors

NCT04814004 ·Status: UNKNOWN ·Phase: PHASE1

CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma

NCT04271410 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

A Clinical Study to Explore CT1194D in Patients With Relapsed/Refractory B-Cell Neoplasms

NCT07200479 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1

Anti-CD19 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphomas

NCT04196205 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/ Refractory B-ALL

NCT06641024 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1

Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With R/R B-ALL

NCT05350787 ·Status: COMPLETED ·Phase: PHASE1

Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma

NCT04271800 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

Phase I Study of pCAR-19B in the Treatment of Adult CD19-positive Relapsed/Refractory B-ALL

NCT04888442 ·Status: UNKNOWN ·Phase: PHASE1

The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors

NCT06911710 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma

NCT04648475 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

CAR-T Cellular Therapy for B Cell Malignancies Involved in CNS

NCT04287309 ·Status: UNKNOWN

A Clinical Study to Explore the Safety and Efficacy of CT0991 in Relapsed/Refractory Acute Myeloid Leukemia

NCT06709131 ·Status: SUSPENDED ·Phase: PHASE1

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research

NCT06393335 ·Status: RECRUITING ·Phase: EARLY_PHASE1

Modified CD19 CAR-T in Patients With Relapsed or Refractory CD19+ B-cell Malignancies

NCT04684472 ·Status: UNKNOWN ·Phase: PHASE1

a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell Malignancies

NCT02846584 ·Status: UNKNOWN ·Phase: PHASE2

A Clinical Study Exploring CT1194C in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

NCT07068906 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1

CD19 & CD20 Bispecific CAR T Cells for Relapsed / Refractory B Cell Hematological Tumors

NCT06503094 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia

NCT06718270 ·Status: RECRUITING ·Phase: EARLY_PHASE1

A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia

NCT06730256 ·Status: RECRUITING ·Phase: EARLY_PHASE1

The Clinical Research of Anti-CD20 CAR-T Cells in Patients With Refractory or Relapsed B Lymphocyte Lymphoma

NCT03576807 ·Status: UNKNOWN ·Phase: PHASE1

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research

NCT06277011 ·Status: RECRUITING ·Phase: EARLY_PHASE1

A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG1101 )

NCT07032324 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1

An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma

NCT05208853 ·Status: UNKNOWN ·Phase: EARLY_PHASE1

Clinical Study of HLA Haploidentical CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL

NCT04887012 ·Status: UNKNOWN ·Phase: PHASE1